#United States #New York #Class Action #Bronstein #Gewirtz & Grossman #Aquestive Therapeutics

Bronstein, Gewirtz & Grossman, LLC Takes Action for Aquestive Therapeutics Investors

New York, April 27, 2026 – In a significant move for investors, Bronstein, Gewirtz & Grossman, LLC, a well-respected law firm focused on investor rights, has announced the filing of a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ: AQST) and select executives of the company. This lawsuit arises from allegations of violations of federal securities laws that allegedly harmed investors who purchased or otherwise acquired securities of Aquestive Therapeutics during the specified class period from June 16, 2025, to January 8, 2026.

Purpose of the Lawsuit

The class action aims at recovering damages for the investors affected during this timeframe. According to allegations in the complaint, the defendants are accused of making materially false and misleading statements about the company’s prospects, particularly regarding the timeline for the approval and launch of the New Drug Application (NDA) for Anaphylm (dibutepinephrine) sublingual film.

The complaint asserts that the defendants overestimated the timeline for the NDA approval and launch, leading investors to falsely believe in the prompt success of the product. Furthermore, they allegedly stated that there was reasonable confidence in receiving approval by the Prescription Drug User Fee Act (PDUFA) date of January 31, 2026, which failed to reflect the significant risks related to human factors affecting the usage and administration of the product.

Allegations Detailed

Key allegations in the class action state that:

• - The approval timeline for Anaphylm was materially overstated.
• - The confident assertions regarding the NDA lacked reasonable basis, indicating a serious disconnect from the actual risks.
• - Concealment or minimization of material issues associated with human factors that could impact regulatory approval occurred.

As a result, investors who relied on these misleading statements suffered significant losses when the true issues became apparent.

Next Steps for Investors

Bronstein, Gewirtz & Grossman, LLC invites all affected investors to consider joining the lawsuit. Those interested in reviewing the full complaint or participating in the action can visit the firm’s website at bgandg.com/AQST. The deadline to request appointment as a lead plaintiff is May 4, 2026. Importantly, involvement in this class action does not necessitate serving as a lead plaintiff to share in any potential recovery.

Legal Representation on a Contingency Basis

The firm operates on a contingency fee basis, meaning clients are only required to cover any out-of-pocket costs and the firm’s fees if they win the case. This approach makes it accessible for investors to pursue legal action without upfront costs, providing an avenue for recovering their losses without the financial burden of legal fees unless successful.

Trust in Bronstein, Gewirtz & Grossman, LLC

With a reputation for championing investor rights, Bronstein, Gewirtz & Grossman, LLC has achieved recoveries totaling hundreds of millions of dollars for investors across the nation. Peretz Bronstein, the founding partner, emphasizes the firm’s commitment to restoring investor capital and maintaining the integrity of the marketplace. They invite investors to stay updated on this case and others through their presence on LinkedIn, X, Facebook, and Instagram.

Investors affected by the alleged misrepresentation of information regarding Aquestive Therapeutics are encouraged to take action and seek the appropriate legal recourse as detailed in this announcement.